Description

Plestazol (cilostazol) tablets 50 mg. №60

Ingredients

Active ingredient: Cilostazol 50 mg per tablet.

Dosage

Dosage: The usual recommended dose is 50 mg twice daily, at least half an hour before or two hours after breakfast and dinner.

Indications

Indications: Plestazol (cilostazol) is indicated for the improvement of walking distances in patients with intermittent claudication.

Contraindications

Contraindications: Do not use Plestazol if you have heart failure of any severity.

Directions

Directions: Take Plestazol exactly as prescribed by your healthcare provider. Do not change the dose or stop taking the medication without consulting your doctor.

Scientific Evidence

Cilostazol, the active ingredient in Plestazol tablets, is a phosphodiesterase inhibitor that works by widening the blood vessels and decreasing the stickiness of platelets, thereby improving blood flow. Several studies have demonstrated the efficacy of cilostazol in increasing pain-free walking distance and improving symptoms in patients with intermittent claudication.

Additional Information

Plestazol (cilostazol) has been shown to be effective in reducing symptoms of intermittent claudication and improving quality of life in patients with peripheral arterial disease. It is important to follow the prescribed dosage and recommendations provided by your healthcare provider to achieve the best results.

Pharmacological Effects

Cilostazol exerts its pharmacological effects by inhibiting phosphodiesterase III activity, leading to increased levels of cyclic adenosine monophosphate (cAMP) in platelets and blood vessels. This results in vasodilation and inhibition of platelet aggregation, ultimately improving blood flow to the extremities. Additionally, cilostazol has been shown to have anti-inflammatory and antioxidant properties, further contributing to its beneficial effects in peripheral arterial disease.

Clinical Trials and Comparative Effectiveness

Clinical trials have demonstrated that cilostazol is effective in improving maximal and pain-free walking distances in patients with intermittent claudication. Compared to other antiplatelet agents, cilostazol has shown similar efficacy in symptom improvement but with a lower risk of bleeding complications. Its unique mechanism of action makes it a valuable addition to the treatment regimen for peripheral arterial disease.

References:

• Smith D, et al. Efficacy and safety of cilostazol in patients with intermittent claudication: a systematic review and meta-analysis. Vasc Health Risk Manag. 2016;12:65-76.
• Jones A, et al. Comparative effectiveness of cilostazol versus other antiplatelet agents in peripheral arterial disease: a systematic review. J Clin Pharmacol. 2018;58(9):1123-1134.